The Claim

In adults with obesity (BMI ≥30 kg/m² or ≥27 kg/m² with comorbidities), a 72-week combination of intravenous bimagrumab (30 mg/kg every 12 weeks) and subcutaneous semaglutide (2.4 mg weekly) results in a mean weight loss of 24.2 kg and a 45.7% reduction in total body fat mass, while preserving lean mass, and produces greater weight loss and fat mass reduction than subcutaneous semaglutide (2.4 mg weekly) alone, which results in a mean weight loss of 16.5 kg and a 27.8% reduction in total body fat mass.

Source: Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial

What the research says

Supports is higher

Support is ahead, but a single strong opposing study can change this.

Supports
87score
Challenges
0score

These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.

Quantitative
1 study reviewed
In plain English

In adults with obesity, a 72-week treatment combining bimagrumab and semaglutide leads to an average weight loss of 24.2 kg and a 45.7% reduction in body fat while maintaining muscle mass, which is greater than the weight loss and fat reduction seen with semaglutide alone.

See the scientific wording

In adults with obesity (BMI ≥30 kg/m² or ≥27 kg/m² with comorbidities), a 72-week combination of intravenous bimagrumab (30 mg/kg every 12 weeks) and subcutaneous semaglutide (2.4 mg weekly) results in a mean weight loss of 24.2 kg and a 45.7% reduction in total body fat mass, while preserving lean mass, surpassing the effects of semaglutide alone, which achieved 16.5 kg weight loss and 27.8% fat mass reduction.

Why this might work

A drug blocks signals that tell fat cells to store energy and muscle cells to break down, while another drug tells the brain to feel full and eat less. This causes the body to burn fat for energy without losing muscle, leading to greater fat loss and more muscle retention than just reducing food intake alone.

Verified mechanismbased on 1 study

What the research says

1 study
  1. Study: Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial

    In people with obesity, taking both drugs together for a year lost more fat and weight than taking just one drug, and kept more muscle intact. The study proved this combo works better than the single drug alone.

Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies

Fit Body Science verdict — we translate health claims into clear verdicts backed by peer-reviewed research.

Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.